In the Dec. 3, 2021, issue of Science, researchers reported that a missense variant that is highly enriched in the Amish population was associated with reduced levels of both LDL cholesterol and fibrinogen. To date, very few variants have been identified that affect more than one risk factor for cardiovascular disease.

Far from the Groundhog Day spectacle of amyloid-targeting antibodies that do little to nothing for patients in trial after trial, researchers have reported success in reducing the risk of Alzheimer’s disease (AD) in unexpected ways. Researchers at the Cleveland Clinic Foundation have discovered that a Viagra prescription was associated with a roughly 70% reduced risk of being diagnosed with AD. And investigators from the University of Washington reported that in the prospective Adult Changes in Thought study, a long-term study into risk and protective factors for dementia, persons who underwent cataract surgery reduced their risk of AD by 30%, an effect that lasted for 10 years after surgery.

In the December 3, 2021, issue of Science, researchers reported that a missense variant that is highly enriched in the Amish population was associated with reduced levels of both LDL cholesterol and fibrinogen. To date, very few variants have been identified that affect more than one risk factor for cardiovascular disease.

Investigators at the University of Wisconsin have decreased anxiety-related behaviors in monkeys with an anxious temperament by treating them with a combination of gene therapy and low doses of the atypical antipsychotic drug clozapine, which is approved for the treatment of schizophrenia and schizoaffective disorder.

Stimulating the innate immune system with defective viral genomes (DVG)-based strategy provided broad-spectrum protection against RNA viral infections, including SARS-CoV-2 and other respiratory diseases in animal models, according to a U.S.-led international collaborative study reported in the Nov. 17, 2021, edition of Cell.

Targeting the epigenetic histone modifier BMI-1 in B cells restored effective humoral immune responses to control chronic viral infection in mice, according to new multicenter Australian study led by immunologists at Monash University in Melbourne, Victoria.

Investigators have identified a previously unrecognized population of senescent cells, called p21high cells, in fat tissue and demonstrated their contributory role in metabolic dysfunction, obesity, insulin resistance and type 2 diabetes.

“I was not always someone who would have advertised probiotics,” Michael Otto told BioWorld. And it’s easy to see why. At this point, probiotics are more often dubious wellness offerings than evidence-based therapeutics. Part of the issue is that the mechanisms by which probiotics are supposed to exert their effects are mostly vague. Molecular mechanisms that could account for claimed health benefits are few and far between. But Otto, who is chief of the pathogen molecular genetics section at the National Institutes of Allergy and Infectious Disease, and his colleagues have identified one such molecular mechanism.

A newly developed antibody-based treatment and a protein-based vaccine for Alzheimer's disease (AD) have both been shown to reduce AD symptoms in mouse models of the disease, British and German researchers reported in the November 15, 2021, edition of Molecular Psychiatry.